19th April 2023
Finnadvance, a company developing organ-on-a-chip disease models and technology, and Ossiform, a medtech company specialising in bone regeneration, today announce their new partnership. Their cooperation allows for the commercialization of a bone-on-chip in vitro model which allows the high throughput screening of drug- or cell-therapies targeting the regeneration of bone tissues.
Ossiform capitalizes on 12 years of scientific research to 3D print highly customizable bone scaffolds which have been validated in several preclinical studies to promote the repair of bone tissue. Their scaffolds made of Tricalcium Phosphate – the main constituent of the bones – provide a physiologically relevant environment that facilitates the growth of bone tissue both in vitro and in vivo.
Finnadvance is the developer of AKITA microfluidic plates, which allow the generation of a wide range of organs-on-chip in medium & high throughput scenarios. While the platform may be used to model any organ, Finnadvance has been focusing on modelling vascularized tissues including the blood-brain barrier, colon, lung and in immuno-oncology with tumour organoids. Finnadvance recently announced their bone-marrow-on-chip as a first step into the field of bone modelling.
Under this partnership, the bone scaffold produced by Ossiform is incorporated into the AKITA microfluidic plate. This newly generated platform will permit the test of bone repair therapies in a high-throughput compatible manner. Additionally, the flow of the Akita system increases the signal-to-noise ratio up to 5 times, which allows the acquisition of higher-quality data.
Finally, the bone-on-chip platform offers high flexibility and is available both as a CRO testing service or may be shipped as a kit for internal research.
Our application note is available by clicking here
Subscribe to our newsletter to be kept updated